1. Calo-Fernandez B, Martinez-Hurtado JL (2012) Biosimilars: company strategies to capture value from the biologics market. Pharmaceuticals 5:1393–1408
2. Choy E, Jacobs IA (2014) Biosimilar safety considerations in clinical practice. Semin Oncol 41:S3–S14
3. Church RF, Druckman MN, Wright E (2009) Biosimilars: What differences between the EU and the US? Scrip World Pharmaceuticals News Supplement
4. Deloitte (2015) Winning with biosimilars Opportunities in global markets. http://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-lshc-biosimilars-whitepaper-final.pdf . Accessed 17 May 2016
5. European Medicines Agency (2016) European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.sp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit . Accessed 05 Oct 2016